MedTech Atlas
Back to medical device regulatory guideAll countries
EuropeENPublic regulatory overview

Russia & EAEU (Eurasian Economic Union)

⚠️ SANCTIONS COMPLIANCE WARNING — READ BEFORE PROCEEDING In light of the geopolitical situation since 2022, Western countries have imposed extensive export controls and financial s...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAModerate benefit

FDA evidence is useful technical and clinical support, but the local authority still performs an independent review.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRModerate benefit

CE evidence provides a strong technical-file template but does not replace the local review.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingPartial / emerging acceptance

NMPA is an emerging reference factor here: it may be accepted or considered for selected products, documents, or review discussions, but the scope must be verified before filing.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: Russia & EAEU (Eurasian Economic Union)
  • Product line: Medical devices
  • Regulator / source: > In light of the geopolitical situation since 2022, Western countries have imposed extensive export controls and financial sanctions on Russia. Before deciding to register and sell medical devices in Russia/EAEU, you must consult export compliance legal counsel (particularly for devices incorporating controlled technology). This document is provided for regulatory process reference only and does not constitute commercial or legal advice. Violations of applicable sanctions regimes can result in severe criminal and civil liability.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Market characteristics: Russia was formerly one of the world's top ten medical device markets (annual market size ~USD 4–5 billion). Since 2022, structural changes have occurred due to sanctions, ruble depreciation, and the withdrawal of Western brands. Import substitution policies (Импортозамещение) are accelerating. Kazakhstan has become a "transit registration hub" for some Western companies seeking to avoid sanctions, though the gray-area compliance risk is substantial.
  • Local requirement: Russia & EAEU medical-device entry should be separated into Roszdravnadzor and EAEU medical-device framework regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

⚠️ SANCTIONS COMPLIANCE WARNING — READ BEFORE PROCEEDING

In light of the geopolitical situation since 2022, Western countries have imposed extensive export controls and financial sanctions on Russia. Before deciding to register and sell medical devices in Russia/EAEU, you must consult export compliance legal counsel (particularly for devices incorporating controlled technology). This document is provided for regulatory process reference only and does not constitute commercial or legal advice. Violations of applicable sanctions regimes can result in severe criminal and civil liability.

Market Overview

  • Population: The five EAEU member states total approximately 185 million (Russia ~145 million, Kazakhstan ~19 million, Belarus ~9.4 million, Armenia ~3 million, Kyrgyzstan ~6.8 million)
  • Healthcare system: Russia's system is centered on mandatory health insurance (OMS, Обязательное медицинское страхование); public hospitals are the primary procurement channel. Kazakhstan has been actively modernizing its healthcare infrastructure in recent years; Belarus operates a Soviet-style national healthcare system.
  • Market characteristics: Russia was formerly one of the world's top ten medical device markets (annual market size ~USD 4–5 billion). Since 2022, structural changes have occurred due to sanctions, ruble depreciation, and the withdrawal of Western brands. Import substitution policies (Импортозамещение) are accelerating. Kazakhstan has become a "transit registration hub" for some Western companies seeking to avoid sanctions, though the gray-area compliance risk is substantial.
  • Regulatory maturity: Medium. The EAEU unified registration system (TR EAEU 017/2011) is established, but enforcement varies across member states. Russia's Roszdravnadzor enforcement is comparatively rigorous. Since 2022, foreign companies operating in Russia face significant compliance and commercial risks.

Market-Entry Logic

Russia & EAEU medical-device entry should be separated into Roszdravnadzor and EAEU medical-device framework regulatory review, classification, local representative / importer, technical file, quality-system evidence, clinical / performance evidence, import, post-market surveillance, reimbursement, procurement and service coverage. For foreign companies, approval is only the compliance entry point; commercial success depends on public procurement, private hospital adoption, distributor coverage, installation / training, service uptime, tenders and reimbursement coding.

Entry layer Key question Practical view
Regulatory route Which product category, risk class, application type, reliance route, or special pathway applies? Confirm the pathway before translating the dossier; route choice drives evidence, timing, fees, inspections, labelling, and change-control obligations
Local execution Who holds the registration, imports, answers regulator questions, manages safety reporting, and controls renewals or variations? Contract structure matters because local agents, sponsors, distributors, or licence holders can control practical market access even when the foreign manufacturer owns the product
Evidence and economics What clinical, quality, performance, HTA, pricing, and budget-impact evidence is needed? Registration evidence and payer evidence should be planned together; otherwise approval may be achieved without reimbursement, tender access, or hospital adoption
Channel access Which payer, hospital, distributor, retail, tender, or private-care channel will create volume? Start with the channel that matches product value and service burden; premium products often need reference sites before broad tender or retail expansion

Main Players and Channel Map

Type Representative players Market meaning
Regulator / review Roszdravnadzor and EAEU medical-device framework Determines approval route, technical evidence, inspections, labelling, post-market duties, renewals, and variations
Payment / procurement OMS public insurance, state procurement, regional tenders and private hospital channels Determines reimbursement, tender economics, price ceilings, purchasing lists, and patient affordability
Companies / channels Shvabe, Rostec-linked suppliers, local importers, regional distributors, public hospitals and EAEU authorised representatives Shows the competitive set, partner universe, distribution power, hospital access points, and local execution benchmarks
End users / buyers Public hospitals, private hospital groups, specialist centers, laboratories, pharmacies, insurers, and regional distributors Determine adoption, tender volume, reference cases, service expectations, and receivables risk
  1. Approval and access are increasingly separate: Technical approval does not guarantee reimbursement, procurement listing, physician adoption, or patient affordability.
  2. Local execution quality is a major differentiator: Strong local regulatory, medical, market-access, distribution, and service teams reduce deficiency, launch, and lifecycle risk.
  3. Evidence expectations are rising: Payers and hospitals increasingly ask for comparative clinical value, real-world evidence, budget impact, and operational service data.
  4. Pricing pressure is structural: sanctions and export-control screening, import substitution, EAEU dossier conversion, payment logistics, local representative risk and public procurement localisation are reshaping launch sequencing and product economics.
  5. Partner control should be managed early: Contracts should protect dossier access, registration ownership, renewal obligations, safety reporting, inventory, and transition rights.

Regulatory Authorities

  • Competent Authority (Russia): Roszdravnadzor (Federal Service for Surveillance in Healthcare, Федеральная служба по надзору в сфере здравоохранения), under the Russian Ministry of Health
  • EAEU level: The Eurasian Economic Commission (EEC, Евразийская экономическая комиссия) issues unified technical regulations
  • Official portals:
  • Key regulations:
    • TR EAEU 017/2011 (Technical Regulation of the Customs Union on the Safety of Medical Devices, Технический регламент Таможенного союза о безопасности медицинских изделий) — the unified EAEU technical regulation applicable across all five member states
    • Russian Federal Law No. 323-FZ "On the Fundamental Principles of the Protection of the Health of Citizens of the Russian Federation"
    • Russian Government Decree No. 1416 (state registration procedure for medical devices)
    • Supplementary national regulations in each member state (Kazakhstan, Belarus, etc. have their own implementing rules)

Device Classification

Local Classification Risk Level EU/FDA Equivalent Notes
Класс 1 (Class 1) Low risk EU Class I / FDA Class I General devices, lowest risk
Класс 2 (Class 2) Medium risk EU Class IIa / FDA Class II Medium risk; conformity assessment body involvement required
Класс 2а (Class 2а) Medium-high risk EU Class IIb / FDA Class II Some literature treats Classes 2 and 2а together
Класс 2б (Class 2б) Higher risk EU Class IIb / FDA Class II–III More rigorous review
Класс 3 (Class 3) High risk EU Class III / FDA Class III Implants, life-sustaining devices, etc.; strictest controls

EAEU classification rules are set out in Annex 1 of TR EAEU 017/2011. They reference but are not fully equivalent to EU MDR classification rules.

Registration Pathway

During the limited-time free period, sign in or register to view the complete medical device country report.